List of 24 most cited papers following a search of "chronic lymphocytic leukaemia" between 2010 and 2014.

Search done July 2015

Porter et al 2011 **N Engl J Med** "Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia." Cited: 414 times
http://www.ncbi.nlm.nih.gov/pubmed /21830940

Stephens et al 2011 **Cell** "Massive genomic rearrangement acquired in a single catastrophic event during cancer development." Cited: 333 times
http://www.ncbi.nlm.nih.gov/pubmed /21215367

Kalos et al 2011 **Sci Transl Med** "T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia." Cited: 287 times http://www.ncbi.nlm.nih.gov/pubmed /21832238

Puente et al 2011 **Nature** "Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia." Cited: 228 times
http://www.ncbi.nlm.nih.gov/pubmed /21642962

Grupp et al 2013 **N Engl J Med** "Chimeric antigen receptor-modified T cells for acute lymphoid leukemia." Cited: 205 times
http://www.ncbi.nlm.nih.gov/pubmed /23527958

Kochenderfer et al 2011 **Blood** "B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells." Cited: 163 times
http://www.ncbi.nlm.nih.gov/pubmed /22160384

Hallek et al 2010 **Lancet** "Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial." Cited: 159 times
http://www.ncbi.nlm.nih.gov/pubmed /20888994

Klein et al 2010 **Cancer Cell** " The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia." Cited: 148 times http://www.ncbi.nlm.nih.gov/pubmed /20060366

Wang et al 2011 **N Engl J Med** " SF3B1 and other novel cancer genes in chronic lymphocytic leukemia." Cited: 141 times http://www.ncbi.nlm.nih.gov/pubmed /22150006

Quesada et al 2011 **Nat Genet** " Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia." Cited: 140 times http://www.ncbi.nlm.nih.gov/pubmed /22158541

Landau et al 2013 **Cell** " Evolution and impact of subclonal mutations in chronic lymphocytic leukemia." Cited: 139 times http://www.ncbi.nlm.nih.gov/pubmed /23415222

Brentjens et al 2011 **Blood** " Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias." Cited: 132 times http://www.ncbi.nlm.nih.gov/pubmed /21849486

Souers et al 2013 **Nat Med** " ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets." Cited: 123 times http://www.ncbi.nlm.nih.gov/pubmed /23291630

Byrd et al 2013 **N Engl J Med** " Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia." Cited: 122 times http://www.ncbi.nlm.nih.gov/pubmed /23782158

Roberts et al 2011 **J Clin Oncol** " Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease." Cited: 98 times http://www.ncbi.nlm.nih.gov/pubmed /22184378

Herishanu et al 2010 **Blood** " The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia." Cited: 97 times http://www.ncbi.nlm.nih.gov/pubmed /20940416

Herman et al 2010 **Blood** "Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals." Cited: 93 times http://www.ncbi.nlm.nih.gov/pubmed /20522708

Brentjens et al 2010 **Mol Ther** "Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial." Cited: 91 times http://www.ncbi.nlm.nih.gov/pubmed /20357779

Herman et al 2011 **Blood** " Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765." Cited: 91 times http://www.ncbi.nlm.nih.gov/pubmed /21422473

Hoellenriegel et al 2011 **Blood** " The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia." Cited: 89 times http://www.ncbi.nlm.nih.gov/pubmed /21803855

Fabbri et al 2011 **J Exp Med** " Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation." Cited: 88 times http://www.ncbi.nlm.nih.gov/pubmed /21670202

Advani et al 2012 **J Clin Oncol** " Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies." Cited: 84 times http://www.ncbi.nlm.nih.gov/pubmed /23045577

Ponader et al 2011 **Blood** " The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo." Cited: 79 times http://www.ncbi.nlm.nih.gov/pubmed /22180443

Wierda et al 2010 **J Clin Oncol** " Ofatumumab as single-agent CD20 immunotherapy in fludarabine-refractory chronic lymphocytic leukemia." Cited: 78 times http://www.ncbi.nlm.nih.gov/pubmed /20194866

For further details and :
http://rforbiochemists.blogspot.co.uk/2015/07/analysing-some-citation-data-in-r.html

Contact: BrennanP@cardiff.ac.uk
Twitter: @brennanpcardiff